All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
EP0042 granted orphan drug designation for the treatment of AML
Following U.S. FDA approval of an investigational new drug application, EP0042, a dual FLT3 and Aurora kinase inhibitor, has been granted orphan drug designation for the treatment of...
ASH 2022 roundup: IDH inhibitors
Here, we summarize safety and efficacy data for enasidenib and ivosidenib and the association between IDH mutations in patients with AML and relapse rates after allo-HSCT is discussed.
Are you a healthcare professional? What is your specialty?
Please select or type your specialty
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.